Correlation Between Bristol Myers and Viracta Therapeutics

Can any of the company-specific risk be diversified away by investing in both Bristol Myers and Viracta Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Bristol Myers and Viracta Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Bristol Myers Squibb and Viracta Therapeutics, you can compare the effects of market volatilities on Bristol Myers and Viracta Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Bristol Myers with a short position of Viracta Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Bristol Myers and Viracta Therapeutics.

Diversification Opportunities for Bristol Myers and Viracta Therapeutics

-0.32

Correlation Coefficient

Bristol Myers  Viracta Therapeutics

Very good diversification

The 3 months correlation between Bristol and Viracta is -0.32. Overlapping area represents the amount of risk that can be diversified away by holding Bristol Myers Squibb and Viracta Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Viracta Therapeutics and Bristol Myers is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Bristol Myers Squibb are associated (or correlated) with Viracta Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Viracta Therapeutics has no effect on the direction of Bristol Myers i.e., Bristol Myers and Viracta Therapeutics go up and down completely randomly.

Pair Corralation between Bristol Myers and Viracta Therapeutics

Considering the 90-day investment horizon Bristol Myers Squibb is expected to generate 0.1 times more return on investment than Viracta Therapeutics. However, Bristol Myers Squibb is 10.06 times less risky than Viracta Therapeutics. It trades about 0.07 of its potential returns per unit of risk. Viracta Therapeutics is currently generating about -0.28 per unit of risk. If you would invest  5,545  in Bristol Myers Squibb on December 29, 2024 and sell it today you would earn a total of  345.00  from holding Bristol Myers Squibb or generate 6.22% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	42.62%
Values	Daily Returns

Bristol Myers Squibb  vs.  Viracta Therapeutics

Bristol Myers Squibb

Risk-Adjusted Performance

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Bristol Myers Squibb are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal primary indicators, Bristol Myers may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Viracta Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Viracta Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Bristol Myers and Viracta Therapeutics

The main advantage of trading using opposite Bristol Myers and Viracta Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Bristol Myers position performs unexpectedly, Viracta Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Viracta Therapeutics will offset losses from the drop in Viracta Therapeutics' long position.

The idea behind Bristol Myers Squibb and Viracta Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.